Statistics by University of Michigan. College of Literature, Science, and the Arts.
Observational Study Medicine®
OPENMedicare beneficiary panel characteristics
associated with high Part D biologic disease-
modifying anti-rheumatic drug prescribing for
older adults among rheumatologists
Jiha Lee
∗
, Chiang-Hua Chang, Raymond Yung, Julie P.W. Bynum
Abstract
The aim of this study was to investigate beneficiary panel characteristics associated with rheumatologists’ prescribing of biologic
DMARDs (bDMARDs) for older adults.
In this retrospective observational study, we used Medicare Public Use Files (PUFs) to identify rheumatologists who met criteria for
high-prescribing, defined as bDMARD prescription constituting ≥20% of their DMARD claims for beneficiaries ≥65years of age. We
first used descriptive analysis then multivariable regression model to test the association of high prescribing of bDMARDs with
rheumatologists’ panel size and beneficiary characteristics. In particular, we quantified the proportion of panel beneficiaries≥75years
of age to assess how caring for an older panel correlate with prescribing of bDMARDs.
We identified 3197 unique rheumatologists, of whom 405 (13%) met criteria for high prescribing of bDMARDs for Medicare
beneficiaries ≥65years of age. The high-prescribers provided care to 12% of study older adults, and yet accounted for 21% of
bDMARD prescriptions for them. High prescribing of bDMARDs was associated with smaller panel size, and their beneficiaries were
more likely to be non-black, ≥75years of age, non-dual eligible, have diagnosis of CHF, however, less likely to have CKD.
Rheumatologists differ in their prescribing of bDMARDs for older adults, and those caring for more beneficiaries ≥75years of age
are more likely to be high-prescribers. Older adults are more prone to the side-effects of bDMARDs and further investigation is
warranted to understand drivers of differential prescribing behaviors to optimize use of these high-risk and high-cost medications.
Abbreviations: bDMARDs = biologic disease-modifying anti-rheumatic drugs, CCW = Chronic Conditions Data Warehouse,
CMS = Center for Medicare & Medicaid Services, FFS = Fee-for-service, HPTC = Healthcare Provide Taxonomy Code, IQR =
interquartile range, NPI = National Provider identifier, PSBS = physician supplier and beneficiary summary, PUF = Public Use Files.
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treatment of rheumatic diseases with improved clinical, func-
tional, and radiographic outcomes.[1,2] Introduction of self-
administered bDMARDs covered by the Medicare Part D
prescription drug benefit greatly expanded access to bDMARDs
to older adults. Although efficacious, bDMARD use is associated
with dose-dependent side effects, such as increased risk of serious
infections and malignancy especially in older adults.[3] In
addition, bDMARDs are costly, accounting for more than half
of all direct medical costs related to rheumatic diseases, and they
are a main driver of Medicare prescription drug spending
growth.[4] Therefore, understanding how bDMARD prescribing
varies among rheumatologists can identify opportunities to
optimize their use that aligns quality of care, outcomes, and cost
considerations in older adults with rheumatic diseases.
Some studies have shown variation in receipt of bDMARDs is
associated with individual patient sociodemographic factors and
preferences, along with reimbursement policies and physician
preferences.[5–8] To our knowledge, there has not been any study
evaluating patient panel characteristics related to rheumatologists
prescribingof bDMARDs. In this study,we identify rheumatologists
whose proportion of all DMARDs prescriptions that are biologics
(bDMARD) for older adults under Medicare Part D is high and the
factors associated with their high bDMARD prescribing.
2. Methods
We used 2 sets of Medicare Public Use Files (PUFs) for this study:
Physician supplier and beneficiary summary (PSBS) file to identify
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Prescriber file to analyze each providers’ proportion of
bDMARDs prescriptions.[9] PUFs are developed by the Center
for Medicare & Medicaid Services (CMS) and contain non-
identifiable claim-specific information made available to
researchers within the public domain.[9] Users of PUFs do not
need to obtain approval or seek a determination that the use of
the public data files meet criteria for being exempt from
Institutional Review Board review.
The PSBS file identifies providers by their National Provider
identifier (NPI) and we used the Healthcare Provide Taxonomy
Code (HPTC) to select for rheumatologists. We obtained
information on aggregate characteristics of all fee-for-service
(FFS) beneficiaries seen by each rheumatologist, including
beneficiary sex, age, race, dual eligibility for Medicaid and
Medicare, and chronic conditions status based on CMS Chronic
Conditions Data Warehouse (CCW).[9] The CCW includes
variables for 27 common chronic conditions and is predefined to
categorize together beneficiaries with claims for either rheuma-
toid arthritis or osteoarthritis.
The Part D Prescriber PUF also identifies providers by their NPI
and has information on total number of prescriptions that were
dispensed for specific drugs.We restricted prescriptions for adults
aged 65 and older. We identified 13 DMARDs, 8 of them
bDMARDs that are most commonly used and have the most
overlap in recommendations by the American College of
Rheumatology for treatment of rheumatic diseases[1,2]: adali-
mumab, etanercept, abatacept, certolizumab, golimumab, ana-
kinra, tocilizumab and tofacitinib. The 5 non-bDMARDs were:
methotrexate, azathioprine, leflunomide, hydroxychloroquine,
and sulfasalazine. For each rheumatologist, we measured the
proportion of bDMARD prescriptions among the total number
of DMARD prescriptions for adults ≥65years of age.
We linked the 2 dataset by the NPI to derive our final analytic
file that contains information on beneficiary panel characteristicsTable 1
Comparison of FFS Medicare beneficiary panel characteristics among
bDMARD prescriptions for adults ≥65years of age.
Variables All rh
No. of rheumatologists, n (%) 3197
Percent bDMARDs
∗
, median% (25th, 75th percentile) 7.2
Panel size, median (25th, 75th percentile) 340











Congestive heart failure 17.1





Percentage bDMARDs=proportion of bDMARD claims among the total number of DMARD clams for
≥65years of age; Panel size= in number of FFS Medicare beneficiaries.
bDMARDs = biologic disease-modifying anti-rheumatic drugs, FFS = fee-for-service.
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and DMARD prescriptions for older adults for each rheumatol-
ogist. We compared Medicare beneficiary panel size, demo-
graphics, and chronic conditions status, among rheumatologists
with varying proportions of bDMARD prescriptions using
descriptive statistics. In particular, we compared high bDMARD
prescribers, defined as rheumatologists with bDMARDs consti-
tuting ≥20% of their DMARD claims, to those with <20%
claims for older adults using t test for continuousmeasures and x2
or Fisher exact for categorical measures. Variables with P value
<.1 in univariate analyses or with clinical significance were then
included in a multivariable logistic regression model to assess
factors associated with high bDMARDs prescribing for older
adults. For the multivariable model, panels were dichotomized
using the 75th percentile value for each demographic characteris-
tic and 20% for each chronic conditions status. If there are <11
beneficiaries or claims for a particular variable the values are
suppressed in PUFs, and in such instances we imputed the mean
value to account for missing variables. Data were analyzed using
Stata/IC 14.2 (Stata Corp).3. Results
We identified 3197 unique rheumatologists, with an average
panel size of 403 (interquartile range [IQR] 359) FFS beneficiaries
(Table 1). On average, most beneficiaries on each rheumatolo-
gists’ panel were women (median 75.1%, IQR 7.5%) and had
diagnosis of arthritis (median 76.9%, IQR 14.6%) broadly
defined by on billing diagnoses.[9] The panel average median
percentage of white was 75.1% (IQR 7.5%), 38.5% (IQR
44.6%) were 75years of age or older, and 16.6% (IQR 16.7%)
were dual eligible for Medicare and Medicaid.
Among all rheumatologists, the proportion of bDMARD
prescriptions was positively skewed with mean of 10.4% (SD
12.7%) and median of 7.2% (IQR 9.9%) (Fig. 1). When divided
in quartiles by proportion of bDMARDs prescribed, the averageall rheumatologists and those who are high-prescribers of Part D
eumatologists High-prescribers (≥20% bDMARDs)
(100) 405 (12.7)
(2.9, 12.8) 30.1 (23.9, 44.4)
(188, 547) 287 (162, 484)
(42.9, 91.1) 78.0 (55.6, 88.3)
(2.7, 14.9) 6.8 (3.0, 14.4)
(1.5, 8.3) 5.4 (2.2, 13.8)
(3.2, 10.0) 6.6 (4.0, 13.4)
(71.1, 78.6) 74.0 (68.2, 78.2)
(31.2, 75.8) 40.2 (31.3, 48.3)
(9.9, 26.6) 17.6 (7.8, 31.0)
(8.0, 13.8) 11.3 (8.8, 15.5)
(14.1, 21.4) 18.2 (4.4, 23.8)
(15.1, 22.6) 17.9 (14.5,22.8)
(23.2, 32.5) 28.4 (23.3, 36.0)
(60.3, 71.7) 66.3 60.0,72.8)
(69.1, 83.7) 75.4 (68.4, 83.1)
adults.
Figure 1. Distribution of rheumatologists by the proportion of bDMARD
prescription for adults ≥65years of age. Among all rheumatologists, the mean
proportion of bDMARD prescription was 10.4% (SD 12.7) and the median was
7.2% (IQR 9.95). There were 405 (12.7%) rheumatologists for whom
bDMARDs constituted ≥20% of their DMARD claims for older adults.
bDMARDs = biologic disease-modifying anti-rheumatic drugs.
Table 2
Medicare beneficiary panel characteristics associated with being
a rheumatologist whose bDMARDs prescription constitute ≥20%




<300 Beneficiaries Reference Reference
300–600 Beneficiaries 0.75 (0.59–0.95) 0.74 (0.57–0.96)
∗
>600 Beneficiaries 0.60 (0.44–0.80) 0.87 (0.41–0.79)
∗
≥80% Female 0.83 (0.63–1.11) 0.87 (0.65–1.16)
≥15% Black 0.91 (0.71–1.17) 0.74 (0.56–0.97)
∗
≥50% 75 y of age or older 1.49 (1.14–1.94) 1.50 1.14–1.99)
∗
<25% Dual eligible 0.70 (0.56–0.88) 0.70 (0.54–0.00
∗
Comorbid conditions
≥20% Cancer 1.29 (0.96–1.73) 0.94 (0.67–1.31)
≥20% Congestive heart failure 1.51 (1.22–1.87) 1.48 (1.15–1.91)
∗
≥20% Chronic kidney disease 1.00 (0.81–1.24) 0.74 (0.57–0.95)
∗
bDMARDs = biologic disease-modifying anti-rheumatic drugs, CI = confidence interval; DMARDS =
biologic disease modifying anti-rheumatic drugs, OR = odds ratio.
∗
Statistically significant with P< .05.
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5.0%) for rheumatologists in the two lowest quartiles, compared
to 19.9% (IQR 14.7%) for those in the top-quartile (Supplemen-
tal Table 1, http://links.lww.com/MD2/A73).
We identified 405 (12.7%) rheumatologists who met criteria
for high bDMARDs prescribing for adults ≥65years of age. The
high prescribing rheumatologists provided care to 11.6% of
beneficiaries ≥65years of age in this study and accounted for
21.5% of all bDMARD claims for older adults under Medicare
Part D. In multivariable logistic analysis, high bDMARD
prescribing for older adults was associated with having a smaller
panel size, and their beneficiaries were more likely to be non-
black, ≥75years of age, non-dual eligible, and have diagnosis of
congestive heart failure, however, less likely to have chronic
kidney disease (Table 2).4. Discussion
In this study, rheumatologists differed in their prescribing of
bDMARDs for older adults, with a small group of providers
accounting for a greater proportion of bDMARD prescriptions.
The high-prescribing rheumatologists had patient panels with
more Medicare beneficiaries over ≥75years of age and fewer
blacks.
Prescribing for older adults pose unique challenges and
variation in bDMARD use may exist as they are more prone
to the additive, sometimes multiplicative, negative effects
associated with high risk medications for reasons of polyphar-
macy and multimorbidity that are the norm rather than the
exception in older adults.[10] Increased life expectancy in the past
few decades, along with advancement in understanding and
treatment have led to a growing population of older adults living
with rheumatic diseases such as rheumatoid arthritis.[11]
Although current guidelines recommend tailoring DMARD
therapy to achieve disease remission in rheumatic diseases,
physician factors influence prescription patterns, at times
independent of disease activity.[8] Moreover, older adults are
less likely to receive aggressive treatment despite some data3
suggesting the relative risk of adverse effects associated with
bDMARD use such as serious infection may be similar across the
older age spectrum which raise concern for poor quality of
care.[12–14] And yet, rheumatologists with higher proportion of
bDMARD prescriptions in this study were more likely to care for
an older panel withmore beneficiaries≥75years of age. Physician
experience and perception of medications are important factors
that influence prescribing behavior and, specialty trained
geriatricians are known to differ in prescribing behavior and
assessment of geriatric syndromes compared to generalists.[15]
Rheumatologists with more experience caring for an older panel
may have more familiarity and comfort in prescribing and
managing risks associated with use of bDMARDs for older
adults. Whether outcomes differ when older adults with
rheumatic diseases are cared for by rheumatologists with higher
proportion of older adults on their panel may be an area of future
investigation.
In addition to an older panel, high prescribers had fewer black
beneficiaries on their panels. Racial disparity in the care of
rheumatic diseases has been observed and is thought to be
propagated by provider, patient, and systemic factors. Patients
under the care of a rheumatologist are more likely to be
prescribed DMARDs,[16] and although Medicare provides
insurance coverage, older blacks may have limited access to or
underutilize specialty care for socioeconomic reasons. The 2015
Rheumatology Workforce Study showed that regional maldistri-
bution of rheumatologists in the Unites States exist,[17] which
may further propagate racial disparity in access to rheumatologic
care. In addition to provider and systemic factors, some data
suggest racial differences in treatment may in part be due to
patient preferences as fewer blacks prefer aggressive treatment
compared to their white counterparts with similar disease
activity.[6]
This study has several limitations common to claims-based
observational analyses. We rely on the completeness and
accuracy of administrative bills recorded by physicians, and
some measure such as disease activity, function, or disability are
not available. In addition, we are limited to variable definitions
provided by CMS in the PUFs and cannot distinguish whether
Lee et al. Medicine (2021) 100:16 Medicinebeneficiaries billed for arthritis have either inflammatory arthritis
or osteoarthritis. The PUFs used in this study summarize patient
characteristics at the level of a physician panel and do not provide
data for more specific individual disease measures but do allow
generation of preliminary estimates on variation in physician
practice using 100% of physicians and beneficiaries in FFS
Medicare. Future work using the research identifiable data will
allow more refined analyses at the patient level.
In conclusion, rheumatologists differ in their propensity to
prescribe bDMARDs for older adults, and although older adults
are less likely to receive aggressive treatment, high-prescribers are
more likely to care for FFS Medicare beneficiaries ≥75years of
age which suggest experience caring for an older panel may
influence prescribing behavior. In addition, high-prescribers are
less likely to care for blacks which may allude to disparity in
access to rheumatologic care independent of insurance coverage.
Further research is needed to understand drivers of differential
prescription patterns of bDMARDs to optimize use of these high-
risk and high-cost medications in older adults.Author contributions
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